Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + selinexor + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- Ruijin Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Azacitidine + selinexor + CHOP is an investigational combination regimen being evaluated for the treatment of treatment-naive peripheral T-cell lymphoma (PTCL), specifically targeting patients with TP53 mutations. This regimen integrates two targeted small-molecule agents—azacitidine, a hypomethylating agent that acts as an epigenetic primer, and selinexor, a selective inhibitor of nuclear export (SINE) that targets XPO1—with the standard-of-care CHOP chemotherapy backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). The combination is part of a precision medicine approach where treatment is guided by the patient's genetic subtype. It is currently being studied in a Phase I/II clinical trial sponsored by Ruijin Hospital.
- Other names
- azacitidine + selinexor + CHOPAzacitidine plus Selinexor with CHOP
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)XPO1 (Exportin-1)DNADNMT (DNA methyltransferase)
Beyond the preview
Go deeper on azacitidine + selinexor + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + selinexor + cyclophosphamide + doxorubicin + vincristine + prednisone.